tardive dyskinesia treatment - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

AppLovin company profile: How Axon AI is taking performance advertising beyond mobile gaming

Infographic showing the Rincon lithium project in Salta, Argentina, with a lithium processing facility and key figures including a US$2.5 billion cost, 60,000-tonne annual capacity, and a 2028 first-production target.

Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline

Supreme Court says children have fundamental right to internet access, rejects blanket bans

Editorial infographic showing affordable fragrance mists becoming a growth area for beauty companies, with product imagery and panels highlighting stronger US mass-market fragrance growth, new launches from major beauty groups, and the key business question of whether lower-priced scents can drive repeat purchases.

Why L’Oréal, Coty and Unilever are betting on affordable fragrance mists

Read More

Pharma Industry News

FDA approves Neurocrine Biosciences’ Ingrezza for tardive dyskinesia

Neurocrine Biosciences has achieved a major milestone with the U.S. Food and Drug Administration (FDA) approving its medication,…

bypharmanewsdaily

April 15, 2017

web analytics